Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AdCOVID · 1 trial · 1 indication
Counts and percentages of subjects with local and systemic events
Counts and percentages of subjects with AEs
| Arm | Type | Description |
|---|---|---|
| Single Low Dose AdCOVID | EXPERIMENTAL | - |
| Single Medium Dose AdCOVID | EXPERIMENTAL | - |
| Single High Dose AdCOVID | EXPERIMENTAL | - |
| Two Low Doses AdCOVID | EXPERIMENTAL | - |
| Two Medium Doses AdCOVID | EXPERIMENTAL | - |
| Two High Doses AdCOVID | EXPERIMENTAL | - |
| Single Dose Placebo | PLACEBO_COMPARATOR | - |
| Two Dose Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AdCOVID | BIOLOGICAL | Administered intranasally |
| Placebo | OTHER | Administered intranasally |
Inclusion Criteria: * Men and women ages 18 to 55 years, inclusive * Good general health status * Screening laboratory results within institutional normal range or Grade 1 abnormality if the Investigator documents clinical insignificance. Grade 2 laboratories may be permissible if considered not cl...
AdCOVID is an investigational vaccine candidate developed by Altimmune, Inc. (ticker ALT) for protection against COVID-19. It was studied in a Phase 1 clinical trial in healthy adults. The vaccine was designed as a single-dose intranasal vaccine, though the program has since been discontinued by the company.
AdCOVID was developed by Altimmune, Inc., a clinical-stage biopharmaceutical company that trades on the Nasdaq under the ticker symbol ALT. Altimmune is based in Gaithersburg, Maryland, and focuses on developing vaccines and immunomodulators for infectious diseases and other conditions.
AdCOVID was in Phase 1 clinical development. A single Phase 1 trial was completed, and no active trials are ongoing. The program has been discontinued by Altimmune, and the vaccine candidate is not approved for any indication.
AdCOVID was evaluated in one Phase 1 clinical trial, NCT04679909, titled "Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)." The trial enrolled 92 healthy adult volunteers in the United States, was randomized, double-blind, and placebo-controlled, and has been completed.
No, AdCOVID is not FDA approved. It was an investigational vaccine candidate that completed a single Phase 1 clinical trial but did not advance to later-stage development. Altimmune discontinued the program, and the vaccine is not available for any indication.